Modified mRNA Formulation and Stability for Cardiac and Skeletal Muscle Delivery.
Modified mRNA Formulation and Stability for Cardiac and Skeletal Muscle Delivery.
复制标题
DOI:
10.3390/pharmaceutics15092176
复制
发表时间:
2023-08-22
期刊:
影响因子:
5.4
通讯作者:
Zangi L
中科院分区:
文献类型:
--
作者:
Żak MM;Kaur K;Yoo J;Kurian AA;Adjmi M;Mainkar G;Yoon S;Zangi L
Directly injecting naked or lipid nanoparticle (LNP)-encapsulated modified mRNA (modRNA) allows rapid and efficient protein expression. This non-viral technology has been used successfully in modRNA vaccines against SARS-CoV-2. The main challenges in using modRNA vaccines were the initial requirement for an ultra-cold storage to preserve their integrity and concerns regarding unwanted side effects from this new technology. Here, we showed that naked modRNA maintains its integrity when stored up to 7 days at 4 °C, and LNP-encapsulated modRNA for up to 7 days at room temperature. Naked modRNA is predominantly expressed at the site of injection when delivered into cardiac or skeletal muscle. In comparison, LNP-encapsulated modRNA granted superior protein expression but also additional protein expression beyond the cardiac or skeletal muscle injection site. To overcome this challenge, we developed a skeletal-muscle-specific modRNA translation system (skeletal muscle SMRTs) for LNP-encapsulated modRNA. This system allows controlled protein translation predominantly at the site of injection to prevent potentially detrimental leakage and expression in major organs. Our study revealed the potential of the SMRTs platform for controlled expression of mRNA payload delivered intramuscularly. To conclude, our SMRTs platform for LNP-encapsulated modRNA can provide safe, stable, efficient and targeted gene expression at the site of injection.
登录
查看更多内容
DOI:
10.1056/nejmoa2034577
发表时间:
2020-12-31
期刊:
The New England journal of medicine
影响因子:
--
作者:
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者:
C4591001 Clinical Trial Group
DOI:
10.1016/j.ymthe.2021.07.014
发表时间:
2021-10-06
期刊:
Molecular therapy : the journal of the American Society of Gene Therapy
影响因子:
--
作者:
Kaur K;Hadas Y;Kurian AA;Żak MM;Yoo J;Mahmood A;Girard H;Komargodski R;Io T;Santini MP;Sultana N;Sharkar MTK;Magadum A;Fargnoli A;Yoon S;Chepurko E;Chepurko V;Eliyahu E;Pinto D;Lebeche D;Kovacic JC;Hajjar RJ;Rafii S;Zangi L
通讯作者:
Zangi L
DOI:
10.1056/nejmoa2113017
发表时间:
2021-11-04
期刊:
The New England journal of medicine
影响因子:
--
作者:
El Sahly HM;Baden LR;Essink B;Doblecki-Lewis S;Martin JM;Anderson EJ;Campbell TB;Clark J;Jackson LA;Fichtenbaum CJ;Zervos M;Rankin B;Eder F;Feldman G;Kennelly C;Han-Conrad L;Levin M;Neuzil KM;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Polakowski L;Mascola JR;Ledgerwood JE;Graham BS;August A;Clouting H;Deng W;Han S;Leav B;Manzo D;Pajon R;Schödel F;Tomassini JE;Zhou H;Miller J;COVE Study Group
通讯作者:
COVE Study Group
影响因子:
12.4
作者:
Kariko, Katalin;Muramatsu, Hiromi;Welsh, Frank A.;Ludwig, Janos;Kato, Hiroki;Akira, Shizuo;Weissman, Drew
通讯作者:
Weissman, Drew
DOI:
10.1056/nejmoa2035389
发表时间:
2021-02-04
期刊:
The New England journal of medicine
影响因子:
--
作者:
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者:
COVE Study Group